IN8BIO, INC.
350 5th Avenue, Suite 5330
New York, New York 10118
January 16, 2024
VIA EDGAR
Securities and Exchange Commission
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Daniel Crawford
| Re: | IN8bio, Inc. (CIK No. 0001740279) Registration Statement on Form S-3 File No. 333-276504 Request for Acceleration of Effective Date |
Ladies and Gentlemen:
Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended, IN8bio, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-3 (the “Registration Statement”) to become effective as of 4:00 p.m. Eastern time, on January 18, 2024, or as soon thereafter as possible, or at such other time as its legal counsel, Cooley LLP, may request by telephone to the Staff.
Once the Registration Statement has been declared effective, please confirm that event with Sarah Curry of Cooley LLP by phone at (212) 479-6652 or by e-mail at sarah.curry@cooley.com.
[Signature page follows]
| Very truly yours, | ||
| IN8bio, Inc. | ||
| /s/ William Ho | ||
| By: | William Ho | |
| Title: | President and Chief Executive Officer | |
[Signature Page to Acceleration Request]